Completed PHASE2 INTERVENTIONAL 1-arm NCT04224402

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Phase 2 Trial to Investigate the Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Sponsor: Yuhong Li

Conditions Pancreatic Cancer Resectable

Interventions mFOLFORINOX

Updated 6 times since 2020 Last updated: Feb 13, 2023 Started: Jan 31, 2020 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer Resectable and is currently completed. Yuhong Li leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2023 — Mar 2023 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Feb 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yuhong Li

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China